Aveo Pharmaceuticals (AVEO)

AVEO Pharma Stock Price & Analysis


AVEO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.06 - $14.95
Previous Close$14.86
Average Volume (3M)1.20M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$77.40M
Total Debt (Recent Filing)$38.68M
Price to Earnings (P/E)-17.6
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.84
Shares Outstanding34,763,127
Standard Deviation0.26
10 Day Avg. Volume409,232
30 Day Avg. Volume1,200,512
Price to Book (P/B)17.92
Price to Sales (P/S)5.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-22.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside0.94% Upside
Rating ConsensusHold
Number of Analyst Covering5


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was AVEO Pharma’s price range in the past 12 months?
AVEO Pharma lowest stock price was $3.06 and its highest was $14.95 in the past 12 months.
    What is AVEO Pharma’s market cap?
    Currently, no data Available
    When is AVEO Pharma’s upcoming earnings report date?
    AVEO Pharma’s upcoming earnings report date is Mar 14, 2023 which is in 105 days.
      How were AVEO Pharma’s earnings last quarter?
      AVEO Pharma released its earnings results on Nov 07, 2022. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.086.
        Is AVEO Pharma overvalued?
        According to Wall Street analysts AVEO Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AVEO Pharma pay dividends?
          AVEO Pharma does not currently pay dividends.
          What is AVEO Pharma’s EPS estimate?
          AVEO Pharma’s EPS estimate is -$0.06.
            How many shares outstanding does AVEO Pharma have?
            AVEO Pharma has 34,763,126 shares outstanding.
              What happened to AVEO Pharma’s price movement after its last earnings report?
              AVEO Pharma reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went up 0.068%.
                Which hedge fund is a major shareholder of AVEO Pharma?
                Among the largest hedge funds holding AVEO Pharma’s share is Caxton Associates LP. It holds AVEO Pharma’s shares valued at 940K.


                  AVEO Pharma Stock Smart Score

                  The AVEO Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aveo Pharmaceuticals

                  AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Gilead Sciences
                  Vertex Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis